NCT02490488View on ClinicalTrials.gov

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Ovarian Cancer
Interventions
DRUG

Masitinib

DRUG

Gemcitabine

DRUG

Placebo

Trial Locations (6)

15706

Complejo Hospitalario Universitario de Santiago, Santiago

16340

Centre hospitalo-universitaire de Beni Messous, Algiers

79031

Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv

84000

Institut Sainte Catherine, Avignon

198255

City Oncology Clinic, Saint Petersburg

CV2 2DX

University Hospital Coventry, Coventry

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY